NoneDecrease
Body weight
Empagliflozin → Body weight
Empagliflozin → Body weight
Evidence profile
NoneDecreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Empagliflozin improves heart function in type 2 diabetes patients
Key finding
Empagliflozin resulted in a significant higher decrease in the primary endpoint E/e' ratio by -1.18 (95% CI -1.72/-0.65; P < 0.0001) compared with placebo.
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Empagliflozin 10 mg/day
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
left ventricular E/e' ratio
Comparator
Placebo
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
Clinical relevance
These findings are clinically significant as they suggest that empagliflozin not only aids in managing blood sugar levels but also improves heart function in patients with type 2 diabetes. This dual benefit could lead to better overall health outcomes and reduced cardiovascular risks in this population.
Keep in mind
The study's sample size may limit generalizability. The duration of the study may not capture long-term effects. Potential confounding factors were not fully controlled.
Published in
Journal Reference
Publication details and source links for this paper.
Jürgen HP, Claus J, Andreas S, et al. Empagliflozin Improves Diastolic Function in Patients with Type 2 Diabetes and Elevated End-Diastolic Pressure. Clinical Research in Cardiology. 2023;112(7):911-922. doi:10.1007/s00392-023-02164-w
Save this study and add notes to your research library.
Main Effects
Empagliflozin significantly decreased the left ventricular E/e' ratio by -1.18 (P < 0.0001).
Empagliflozin led to a significant decrease in body weight (P < 0.001).
Empagliflozin resulted in a significant decrease in HbA1c (P < 0.001).
Empagliflozin significantly increased hemoglobin levels (P < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and Body weight, HbA1c, Hematocrit, and 4 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Body weight
- HbA1c
- Hematocrit
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
7
Evidence pairs
7
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
7
Evidence pairs
267
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 7 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneDecrease
HbA1c
Empagliflozin → HbA1c
Empagliflozin → HbA1c
Evidence profile
NoneDecreaseGlycemic Control
Unlock full evidence details
NoneIncrease
Hematocrit
Empagliflozin → Hematocrit
Empagliflozin → Hematocrit
Evidence profile
NoneIncreaseClinical Outcomes
Unlock full evidence details
NoneIncrease
Hemoglobin
Empagliflozin → Hemoglobin
Empagliflozin → Hemoglobin
Evidence profile
NoneIncreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
left ventricular E/e' ratio
Empagliflozin → left ventricular E/e' ratio
Empagliflozin → left ventricular E/e' ratio
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongIncrease
Red Blood Cells
Empagliflozin → Red Blood Cells
Empagliflozin → Red Blood Cells
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
NoneDecrease
Uric Acid
Empagliflozin → Uric Acid
Empagliflozin → Uric Acid
Evidence profile
NoneDecreaseMetabolic Health
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Empagliflozin improved the left ventricular E/e' ratio significantly.
- Participants experienced a significant reduction in body weight.
- HbA1c levels decreased significantly with empagliflozin treatment.
Who this applies to
- Adults with type 2 diabetes.
- Patients experiencing elevated end-diastolic pressure.
Keep in Mind
- Results may not apply to populations outside the study demographics.
- Long-term effects of empagliflozin were not assessed in this trial.
- Further studies are needed to confirm these findings in diverse populations.
Between the Lines
- The study's sample size may limit generalizability.
- The duration of the study may not capture long-term effects.
- Potential confounding factors were not fully controlled.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and left ventricular E/e' ratio, SGLT2 Inhibitors and Red Blood Cells.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
left ventricular E/e' ratio Evidence Hub
All studies measuring left ventricular E/e' ratio
1 studies
outcome_hubMeasures left ventricular E/e' ratio as a key outcome.
Red Blood Cells Evidence Hub
All studies measuring Red Blood Cells
1 studies
outcome_hubMeasures Red Blood Cells as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
1 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Empagliflozin and left ventricular E/e' ratio
Intervention: EmpagliflozinOutcome: left ventricular E/e' ratio
1 results
All studies on Empagliflozin and Red Blood Cells
Intervention: EmpagliflozinOutcome: Red Blood Cells
1 results
All studies on Empagliflozin
Intervention: Empagliflozin
1 results
All studies measuring left ventricular E/e' ratio
Outcome: left ventricular E/e' ratio
1 results
All studies measuring Red Blood Cells
Outcome: Red Blood Cells
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Emerging Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 41.7 | neutral | ConsensusScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors affect body weight?
Emerging Evidence
SGLT2 Inhibitors may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 48.4 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Empagliflozin improve red blood cells?
Emerging Evidence
Empagliflozin appears to improve Red Blood Cells.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Red Blood Cells
EvidenceScore™ Emerging | EvidenceScore™ 53.0 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Empagliflozin improve left ventricular e/e' ratio?
Emerging Evidence
Empagliflozin appears to improve left ventricular E/e' ratio.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
left ventricular E/e' ratio
EvidenceScore™ Emerging | EvidenceScore™ 53.0 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesEmpagliflozin may improve nighttime blood sugar patterns in type 1 diabetesEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetesEmpagliflozin reduces body fluid volume in type 2 diabetes patientsGlutamine supplementation may decrease glycaemia in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.